AN2 Therapeutics Launches with $12 Million in Series A Funding and Announces a Strategic Partnership with Brii Biosciences
AN2's Series A focused on advancing novel treatments for infectious diseases of global significance
AN2 grants license to Brii Biosciences for study of the lead antibacterial program in greater China
MENLO PARK, Calif., Nov. 21, 2019 -- (Healthcare S... Biopharmaceuticals, Venture Capital AN2 Therapeutics, Brii Biosciences
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: China Health | Funding | Grants | Infectious Diseases | Men | Partnerships | Pharmaceuticals | Study | Venture Capital